Document |
Document Title |
WO/2019/088374A1 |
The present invention relates to a vitamin E-based amphipathic compound, a method for producing same, and a method for extracting, solubilizing, stabilizing, or crystalizing a membrane protein using same. By using a compound according to...
|
WO/2019/079160A1 |
The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and ...
|
WO/2019/079706A1 |
Provided herein are aminoglycosides for the treatment of infections, and pharmaceutical compositions, methods, kits, and uses thereof. Also provided are a methods of making aminoglycosides that enables late-stage derivatization of the C6...
|
WO/2019/079613A1 |
The present disclosure relates to novel methods for preparing antibacterial sisomicin-type aminoglycoside compounds, as well as to related intermediates, and crystal forms thereof, useful in such methods.
|
WO/2019/074171A1 |
The present invention relates to an amphiphilic compound having a dendronic hydrophobic group, a method for preparing the same, and a method for extraction, solubilization, stabilization, or crystallization of a membrane protein by using...
|
WO/2019/074833A1 |
The present disclosure relates to sugar-linked amino acids and processes for preparing the same. The sugar-linked amino acids may be used for solid-phase peptide synthesis. A sugar compound and an amino acid compound having a nucleophili...
|
WO/2019/071250A1 |
A steviol glycoside composition with reduced surface tension. The reduced surface tension steviol glycoside composition includes an aqueous solution of a steviol glycoside and a surface tension reducing compound in an amount effective to...
|
WO/2019/071188A1 |
A readily dissolvable steviol glycoside composition comprising a steviol glycoside and a dissolution enhancer compound in an amount effective to increase dissolution of the steviol glycoside.
|
WO/2019/071182A1 |
A solubilized steviol glycoside composition including one or more steviol glycosides and one or more steviol glycoside solubility enhancers can be used as a sweetener composition to sweeten other compositions (sweetenable compositions) s...
|
WO/2019/069297A2 |
Activity-based probes that can be used to selectively identify and characterize enzymes that are involved in different phases of xenobiotic metabolism in a host and its microbiota population(s) are described. The activity-based probes de...
|
WO/2019/071220A1 |
A steviol glycoside composition having modified sensory attributes including reduced sweetness linger and/or increased sweetness intensity. The steviol glycoside composition comprises a steviol glycoside and a sensory modifier compound i...
|
WO/2019/063955A1 |
The present invention concerns the compounds of the following formula (I): (I) in which: - X represents an oxygen atom, a sulfur atom, a nitrogen atom or a CH radical, - The X--Y bond and Y are absent if X represents an oxygen or sulfur ...
|
WO/2019/060634A1 |
The invention features methods for the treatment of cystinosis and other cysteamine sensitive disorders in a subject including administration of a disulfide convertible to cysteamine in vivo. The methods can include the separate administ...
|
WO/2019/057165A1 |
Disclosed in the present invention are a novel crystal form of idarubicin hydrochloride monohydrate, a method for preparing the novel crystal form, a pharmaceutical composition containing the novel crystal form, and a medical use of the ...
|
WO/2019/056097A1 |
Described herein are markers, conjugates, compositions and methods for hypoxia imaging, mapping, and therapy. A compound comprising bio-reductively activated (BA) arm, linker arm and a mapping click wherein BA contains one for more of su...
|
WO/2019/056098A1 |
Described herein are bioreductively- activated compounds, their prodrugs, radiopharmaceuticals, the compositions, and their application in multimodal theranostic management of hypoxia diseases including cancer.
|
WO/2019/053700A2 |
Probe embodiments for identifying analytes involved in biofuel or bioenergy production, bioremediation, or nutrient cycling as well as methods of making and use are described herein. In some embodiments, probes identifying cellulose degr...
|
WO/2019/047848A1 |
The invention belongs to the field of quality analysis and control of traditional Chinese medicine, and provides a method for separating eighteen components in a traditional Chinese medicine composition, comprising: (1) preparing the tra...
|
WO/2019/051322A1 |
Improved processes for the preparation of tubulysin compounds, tubulysin drug linker compounds, and their intermediates are disclosed.
|
WO/2019/046638A1 |
Nutritional supplement compositions for enhancement of day-time mood and night-time sleep quality are disclosed. A nutritional supplement composition can include one or more of plant material from Corn grass, Griffonia seed, vitamin B3 (...
|
WO/2019/046126A1 |
Provided herein are aminoglycoside compounds, such as compounds of formula (I), (II), (III), (IV), (IVa), (V), (VI), (VIIa), or (VIIb) or pharmaceutically acceptable salts, solvates, stereoisomers, or tautomers of any of the foregoing, u...
|
WO/2019/038366A1 |
The present invention relates to a method for preparing at least one oligosaccharide, comprising a step of ultrasound irradiation, at a frequency higher than 100 kHz, of an alcohol composition comprising at least one saccharide monomer a...
|
WO/2019/036566A1 |
Described herein are methods of treating fibrosis and fibrotic diseases with certain aminoglycosides, e.g., kasugamycin derivatives thereof.
|
WO/2019/032936A1 |
Provided are lincosamide compounds for the treatment of infectious diseases. The lincosamides described herein are modified at the amino acid (southern) region. The lincosamides may have further modification at the C-1 and C-7 positions ...
|
WO/2019/032956A1 |
Provided are lincosamide compounds for the treatment of infectious diseases. The lincosamides described herein are modified at the C-7 position of the aminooctose (northern) region, thus distinguishing them from lincomycin and clindamyci...
|
WO/2019/031754A1 |
The present invention relates to a novel ospemifene derivative compound in which a sugar is added to ospemifene as one kind of selective estrogen receptor modulator (hereinafter, SERM), and to a preparation method for the compound. The o...
|
WO/2019/018940A1 |
Natural sweetener compositions are disclosed, which generally include steviol glycosides extracted from a Stevia rebaudiana plant and an amino acid component consisting of free glycine. The natural sweetener compositions may optionally f...
|
WO/2019/019985A1 |
The present invention falls within the technical field of selenium-containing compounds. Disclosed are selenium-containing compounds - selenocarbohydrate, selenoglucoside - and preparation methods therefor. The method comprises the steps...
|
WO/2019/012476A1 |
The present invention generally refers to novel intermediate polysaccharide units, useful for the preparation of polysaccharide antigen of GBS Ia, Ib and III; the invention also refers to a process for their preparation and their use as ...
|
WO/2019/011914A1 |
The present invention relates to the novel use of saponins comprising acetyl residues on one of their sugar residues. These saponins are able to enhance the transfection efficiency to a surprisingly much higher extent than already known ...
|
WO/2019/010563A1 |
The invention relates to the use of a compound having the structure of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, for treating or preventing nephrolithiasis in patients. The invention further relates to an assa...
|
WO/2019/008441A1 |
Provided are a compound including a cleavable linker, a use thereof, and an intermediate compound for preparing the same, and more particularly, the compound including a cleavable linker of the present invention may include an active age...
|
WO/2019/007999A1 |
The present invention provides protected tetrasaccharides, their process of preparation and their use in the synthesis of oligosaccharides, in particular fragments of O-antigens from Shigella flexneri, for example of serotype la, lb, 2a,...
|
WO/2019/006244A1 |
The present disclosure provides a method of producing enhanced amounts of rebaudioside M (Reb M) from various steviol glycosides utilizing the hydrolytic activity of beta-glucosidase. More specifically, the present disclosure provides an...
|
WO/2018/233092A1 |
A method for preparing Rubusoside, comprising the following steps: grinding raw materials, performing flash extraction, double centrifugation, macroporous resin purification, desorption, enzymolysis, organic membrane grading decolorizati...
|
WO/2018/237327A1 |
Disclosed herein are methods and compounds for treating glioblastoma with iniparib. Also disclosed herein is a method of selecting subjects having a glioblastoma for treatment based on a biomarker panel.
|
WO/2018/237136A1 |
Disclosed are anti-cancer compounds and imaging agents. More specifically, the disclosed agents target carbonic anhydrase IX and XII and their use in the treatment of cancer, in particular breast cancer. Specific compounds are those that...
|
WO/2018/229663A1 |
The invention provides fluorescence-quenched substrates of exo-glycosidase enzymes. The invention also provides methods for imaging exo-glycosidase enzymes activity within cells.
|
WO/2018/231091A1 |
Field of use: the invention relates to combinatorial chemistry, pharmaceutics and cosmetology, and allows the synthesis of novel combinatorial libraries of antibiotic derivatives for use in pharmaceutics and cosmetology. Essence of the i...
|
WO/2018/231089A1 |
Field of use: The invention relates to organic and bio-organic combinatorial chemistry, specifically to new combinatorial libraries of polysaccharide derivatives and to supramolecular structures based thereon, which have high biological ...
|
WO/2018/232334A1 |
The present inventions provides drug-drug conjugates, drug-porphyrin conjugates, nanoparticles of the conjugates, as well as modified nanoparticles having PEGylated exteriors or encapsulated by red blood cell vesicles. The conjugates, na...
|
WO/2018/217808A1 |
The present invention provides certain lipo-glycopeptide cleavable derivatives and methods for using the same for the treatment of bacterial infections, for example, pulmonary bacterial infections. The LGPC derivatives include a cleavabl...
|
WO/2018/216013A1 |
The present invention provides turn-ON dioxetane-based chemiluminescence probes based on the Schapp's adamantylidene-dioxetane probe, which emit light in the near-infrared (NIR) region and are therefore useful for in vivo imaging, as wel...
|
WO/2018/217769A1 |
The present invention is generally directed to processes for producing lactitol granulates. The present invention is also directed to lactitol granulates exhibiting one or more desirable and improved properties as compared to prior lacti...
|
WO/2018/217700A1 |
The invention relates to glucuronide prodrug compounds of Janus kinase (JAK) inhibitors having formula (I), where W1, R1 and A1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods ...
|
WO/2018/217699A1 |
The invention relates to thiocarbamate prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula (I) wherein R1, R2, R3, R4 and n are as defined. The invention also relates to pharmaceutical compositions comprising...
|
WO/2018/213279A1 |
Methods of preparing highly purified steviol glycosides, particularly rebaudiosides M, D, E and / are described. The methods include utilizing enzyme preparations and recombinant microorganisms for converting various staring compositions...
|
WO/2018/205286A1 |
Provided is a conjugate containing a fluorescent chromophore, which has any structure selected from C1 to C3. The conjugate containing the fluorescent chromophore provided by the present invention comprises one fluorescent chromophore an...
|
WO/2018/207113A1 |
The present invention relates to an industrially feasible and economically viable process for preparation of Bexagliflozin of formula V in significantly high yield and purity.
|
WO/2018/209255A1 |
Aspects of the invention relate to novel synthetic compounds having binding affinity with galectin proteins.
|